MSOS ETF Analysis And what to watch for MSOS ETF

Conservative group opposing PBM reform spends record number on lobbying

WASHINGTON — A conservative group advocating against changing how pharmacy middlemen operate spent more than $1 million on lobbying last quarter — its highest-ever spend

July 18, 2023

Breakthrough humanized mouse model offers new insights for immunotherapy development

A breakthrough for biomedical research promises new insight into immunotherapy development and disease modeling.

July 5, 2024

FDA expands label for Novartis and Roche’s blockbuster, converts EMD Serono’s NSCLC drug to full approval

The FDA on Friday signed off on an expanded label for Novartis and Roche’s blockbuster Xolair (omalizumab) and on Thursday converted the accelerated to full

February 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.